Difference between revisions of "Radiotherapy toxicity management"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) (Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
m |
||
| Line 9: | Line 9: | ||
{{TOC limit|limit=4}} | {{TOC limit|limit=4}} | ||
| + | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.''' | ||
| + | ==ASCO== | ||
| + | *'''1999:''' Hensley et al. [https://doi.org/10.1200/jco.1999.17.10.3333 American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants] [https://pubmed.ncbi.nlm.nih.gov/10506637/ PubMed] | ||
[[Category:General reference pages]] | [[Category:General reference pages]] | ||
[[Category:Radiation]] | [[Category:Radiation]] | ||
[[Category:Supportive oncology]] | [[Category:Supportive oncology]] | ||
Revision as of 00:46, 26 October 2023
| Focus editor | Associate editor | ||
|---|---|---|---|
 |
Michael K. Rooney, MD MD Anderson Cancer Center Houston, TX, USA |
 |
Danielle S. Bitterman, MD Dana-Farber Cancer Institute Boston, MA, USA |
The purpose of this page is to address the management of toxicity from radiation therapy.
To be created!
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.